Small-Cell Lung Cancer With Later Brain and Other Metastases in a Woman With COPD
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Small Cell Lung Cancer
- Sex
- female
- Spread to
- central nervous system
- Treatment
- chemotherapy and immunotherapy
- Outcome
- In Memory
Treatment course, step by step
- Started carboplatin and etoposide chemotherapy with atezolizumab 20 days after hospital admission.
- During treatment she developed immune-related encephalitis.
- The cancer later showed extensive central-nervous-system and other organ metastases.
What happened, in summary
A 50-year-old woman with a heavy smoking history presented with chest pain radiating to her shoulder and hoarseness. Imaging showed a large left-lung hilar tumor with extensive lymph-node involvement. Lung-function testing also led to a diagnosis of COPD. Biopsy confirmed small-cell lung carcinoma.
She began carboplatin and etoposide chemotherapy with atezolizumab immunotherapy only 20 days after her hospital admission. During treatment, she developed seizures, memory loss, and disorientation. Brain imaging and spinal-fluid testing supported a diagnosis of atezolizumab-related autoimmune encephalitis.
Her neurologic condition continued to deteriorate, and the cancer later showed severe metastases to the central nervous system and other organs, establishing metastatic disease. She died from sepsis 8 months after the lung-cancer diagnosis. Her course was complicated both by aggressive small-cell lung cancer and by a serious immune-related neurologic adverse event.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Lung Cancer 384 stories
- Atezolizumab for Lung Cancer 18 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer